Valuation: Chugai Pharmaceutical Co., Ltd.

Capitalization 12,827B 81.37B 69.34B 63.55B 60.13B 111B 7,781B 112B 750B 294B 3,698B 305B 299B P/E ratio 2026 *
25.1x
P/E ratio 2027 * 21.8x
Enterprise value 11,857B 75.22B 64.1B 58.74B 55.58B 103B 7,192B 104B 693B 272B 3,418B 282B 276B EV / Sales 2026 *
8.58x
EV / Sales 2027 * 7.63x
Free-Float
38.12%
Yield 2026 *
1.75%
Yield 2027 * 1.98%
1 day-2.00%
1 week-5.47%
Current month-3.97%
1 month-10.16%
3 months-13.61%
6 months+3.63%
Current year-5.45%
1 week 7,727
Extreme 7727
8,248
1 month 7,402
Extreme 7402
9,013
Current year 7,402
Extreme 7402
10,700
1 year 5,942
Extreme 5942
10,700
3 years 3,580
Extreme 3580
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 2020-12-31
Director of Finance/CFO - 2024-03-27
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 81 2015-02-28
Director/Board Member 68 1993-02-28
Director/Board Member 67 2019-02-28
Change 5d. change 1-year change 3-years change Capi.($)
-2.00%-5.47%-5.17%+120.67% 83.36B
+2.37%+2.27%+34.76%+127.27% 862B
+1.28%+0.03%+45.42%+39.30% 533B
+2.51%-0.14%+12.60%+41.80% 358B
-0.94%-0.38%+22.40%+11.63% 328B
+1.82%+1.75%+34.26%+15.30% 286B
+1.93%+1.81%+27.49%+25.19% 279B
+0.98%-0.65%+47.91%-4.41% 275B
-1.17%+4.79%-33.27%-48.68% 210B
+2.03%+3.84%+26.49%+44.77% 178B
Average +0.19%-0.32%+21.29%+37.28% 339.22B
Weighted average by Cap. +0.24%-0.51%+27.70%+49.37%

Financials

2026 *2027 *
Net sales 1,382B 8.77B 7.47B 6.85B 6.48B 12.01B 838B 12.11B 80.82B 31.71B 398B 32.92B 32.21B 1,521B 9.65B 8.22B 7.54B 7.13B 13.22B 923B 13.33B 88.95B 34.9B 439B 36.23B 35.45B
Net income 511B 3.24B 2.76B 2.53B 2.39B 4.44B 310B 4.47B 29.85B 11.71B 147B 12.16B 11.9B 589B 3.74B 3.18B 2.92B 2.76B 5.12B 357B 5.16B 34.43B 13.51B 170B 14.02B 13.72B
Net Debt -970B -6.16B -5.25B -4.81B -4.55B -8.43B -589B -8.5B -56.73B -22.26B -280B -23.11B -22.61B -1,226B -7.78B -6.63B -6.07B -5.75B -10.65B -744B -10.75B -71.7B -28.13B -353B -29.2B -28.57B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
26-05-12 7,794.00 ¥ -2.00% 2,123,700
26-05-11 7,953.00 ¥ +0.67% 3,038,800
26-05-08 7,900.00 ¥ -2.41% 4,228,200
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,794.00JPY
Average target price
10,096.67JPY
Spread / Average Target
+29.54%

Quarterly revenue - Rate of surprise